CAV Regimen for R/R Ph- B-ALL
Study Details
Study Description
Brief Summary
This study aims to investigate the efficacy and safety of cladribine, venetoclax combined with cytarabine and venetoclax (CAV regimen) for relapsed/refractory (R/R) Philadelphia Chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Relapse is common in Ph- B-ALL and a proportion of patients present refractory to initial treatment. Treatments for these patients consist immunotherapy and conventional chemotherapy. The former is too expensive and the latter has a low remission rate. Treatment for R/R Ph- B-ALL still remains a challenge. The efficacy and safety of cladribine, venetoclax and cytarabine (CAV) has not been explored in ALL. Thus investigators design such a clinical trial to investigate the efficacy and safety of CAV regimen for R/R Ph- B-ALL.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: CAV regimen
|
Drug: cladribine, cytarabine,venetoclax
Cladribine 5 mg/m2/day, cytarabine 20mg q12h, venetoclax 100mg d1, 200 d2, 400 mg/day from day 3 to day 21.
|
Outcome Measures
Primary Outcome Measures
- Overall response rate (ORR) [ORR assessment is measured on days 21 from the start of CAV regimen]
The overall response (completed remission, completed remission with incomplete blood count recovery)
Secondary Outcome Measures
- Overall Survival (OS) [2 years]
OS is measured from the time of enrollment to this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.
- Progression-Free Survival (PFS) [2 years]
PFS is measured from the time of enrollment to this study to progression or death.
- Adverse events [1 month]
It is evaluated and graded according to CTCAE 5.0.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Aged 13-65 years old.
-
Patients diagnosed with R/R Ph- B-ALL.
-
Patients with ALL must meet one of the following criteria, A or B: A: Refractory ALL disease was defined as follows: (1) failure to attain CR following exposure to at least 1 courses of standard induction therapy; B: Relapsed ALL disease was defined as follows: (1) reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of ≥ 5% blasts in the BM not attributable to another cause (e.g., BM regeneration after consolidation therapy); or (3) extramedullary relapse.
-
ECOG performance status score less than 2.
-
Expected survival time ≥ 12 weeks.
-
Patients without serious heart, lung, liver, or kidney dysfunction.
-
Able to understand and provide informed consent.
Exclusion Criteria:
-
Patients who are allergic to the study drug or drugs with similar chemical structures.
-
Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.
-
Active infection.
-
Active bleeding.
-
Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.
-
Patients with mental disorders or other conditions.
-
Liver function abnormalities (total bilirubin > 1.5 times of the upper limit of the normal range, ALT/AST > 2.5 times of the upper limit of the normal range or patients with liver involvement whose ALT/AST > 1.5 times of the upper limit of the normal range), or renal dysfunction (Ccr<50ml/h).
-
Patients with a history of clinically significant QTc interval prolongation (male > 450 ms; female > 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
-
Surgery on the main organs within the past six weeks.
-
Drug abuse or long-term alcohol abuse that would affect the evaluation results.
-
Patients who have received organ transplants.
-
Patients not suitable for the study according to the investigator's assessment.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | China | 215006 |
Sponsors and Collaborators
- The First Affiliated Hospital of Soochow University
- Jining Medical University
- The Second People's Hospital of Huai'an
- First Affiliated Hospital Bengbu Medical College
- Northern Jiangsu Province People's Hospital
- Affiliated Hospital of Nantong University
- Suzhou Hospital of Traditional Chinese Medicine
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SZBALL01